Hospital · Private company
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Track this companyFree. Adds Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins to your Dealase workspace and tells you when its record changes.
Clinical trials2525 recruiting or active
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Clinical trials25
- Circulating Tumor DNA (ctDNA) in High Grade Upper Tract Urothelial Cancer (UTUC)NOT_YET_RECRUITING · started Dec 1, 2026ClinicalTrials.gov NCT07793240 · fetched Nov 12, 2026
- Study of Sarilumab With Immune Checkpoint Inhibitor Rechallenge in Patients With Clinically Significant Immune Related Adverse EventsPHASE2 · NOT_YET_RECRUITING · started Dec 1, 2026ClinicalTrials.gov NCT07836101 · fetched Nov 12, 2026
- GLAD-KE GLioma Biomarker and Safety Assessment During Dietary Ketone Elevation Subtitle: A Surgical Biomarker Discovery Study of Ketogenic Therapy in Recurrent GliomaNA · NOT_YET_RECRUITING · started Nov 5, 2026ClinicalTrials.gov NCT07852975 · fetched Nov 12, 2026
- Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract CancerPHASE2 · NOT_YET_RECRUITING · started Nov 1, 2026ClinicalTrials.gov NCT07793253 · fetched Nov 12, 2026
- Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR Locally Advanced Rectal CancerPHASE2 · NOT_YET_RECRUITING · started Nov 1, 2026ClinicalTrials.gov NCT07580339 · fetched Nov 12, 2026
- A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)PHASE1 · RECRUITING · started Oct 28, 2026ClinicalTrials.gov NCT07430202 · fetched Nov 12, 2026
- Exercise in Prostate CancerNA · RECRUITING · started Oct 16, 2025ClinicalTrials.gov NCT06165302 · fetched Nov 12, 2026
- The COSMYC Trial (COmbined Suppression of MYC)PHASE2 · RECRUITING · started Aug 19, 2025ClinicalTrials.gov NCT06922318 · fetched Nov 12, 2026
- Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian CancerPHASE2 · ACTIVE_NOT_RECRUITING · started Feb 6, 2025ClinicalTrials.gov NCT06617923 · fetched Nov 12, 2026
- Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific AntibodiesEARLY_PHASE1 · RECRUITING · started Sep 19, 2024ClinicalTrials.gov NCT06398457 · fetched Nov 12, 2026
- Exploration of Personalized Biomarkers During Neoadjuvant Radiation Therapy for Spinal and Sacral ChordomaRECRUITING · started Jun 14, 2024ClinicalTrials.gov NCT06463262 · fetched Nov 12, 2026
- DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)PHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Feb 12, 2024ClinicalTrials.gov NCT06027086 · fetched Nov 12, 2026
- Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).PHASE2 · ACTIVE_NOT_RECRUITING · started Dec 14, 2023ClinicalTrials.gov NCT05977907 · fetched Nov 12, 2026
- Safety and Efficacy of Allogeneic HPV-specific T Cells in Adults With Recurrent or Metastatic HPV16+ CancersPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Oct 18, 2023ClinicalTrials.gov NCT04713046 · fetched Nov 12, 2026
- Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older PatientsPHASE1 · ACTIVE_NOT_RECRUITING · started Jul 6, 2023ClinicalTrials.gov NCT05823571 · fetched Nov 12, 2026
- Liquid Biopsy-informed Precision Oncology Study to Evaluate Utility of Plasma Genomic Profiling for Therapy SelectionRECRUITING · started Jan 27, 2023ClinicalTrials.gov NCT05585684 · fetched Nov 12, 2026
- Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic CancerPHASE1 · ACTIVE_NOT_RECRUITING · started Apr 11, 2022ClinicalTrials.gov NCT05013216 · fetched Nov 12, 2026
- Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular CarcinomaPHASE1 · ACTIVE_NOT_RECRUITING · started May 28, 2021ClinicalTrials.gov NCT04658147 · fetched Nov 12, 2026
- Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 InhibitorPHASE2 · ACTIVE_NOT_RECRUITING · started Nov 16, 2018ClinicalTrials.gov NCT03607890 · fetched Nov 12, 2026
- A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission MaintenancePHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Sep 5, 2017ClinicalTrials.gov NCT03114865 · fetched Nov 12, 2026
- Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker AnalysisPHASE2 · ACTIVE_NOT_RECRUITING · started Mar 1, 2017ClinicalTrials.gov NCT03047135 · fetched Nov 12, 2026
- Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate CancerPHASE2 · ACTIVE_NOT_RECRUITING · started May 3, 2016ClinicalTrials.gov NCT02452008 · fetched Nov 12, 2026
- Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the PancreasPHASE2 · ACTIVE_NOT_RECRUITING · started Mar 28, 2016ClinicalTrials.gov NCT02451982 · fetched Nov 12, 2026
- Subventricular Zone (SVZ) and Temozolomide in Glioblastoma MultiformePHASE2 · ACTIVE_NOT_RECRUITING · started Jul 8, 2014ClinicalTrials.gov NCT02177578 · fetched Nov 12, 2026
- Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast CancerPHASE2 · ACTIVE_NOT_RECRUITING · started Jan 30, 2014ClinicalTrials.gov NCT01937117 · fetched Nov 12, 2026